Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/8314
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDassah, Sylvester-
dc.contributor.authorSakyi, Samuel A.-
dc.contributor.authorFrempong, Margaret T.-
dc.contributor.authorLuuse, Arnold T.-
dc.contributor.authorEphraim, Richard K. D.-
dc.contributor.authorAnto, Enoch O.-
dc.contributor.authorOduro, Abraham-
dc.date.accessioned2022-06-13T10:42:09Z-
dc.date.available2022-06-13T10:42:09Z-
dc.date.issued2015-12-
dc.identifier.issn23105496-
dc.identifier.urihttp://hdl.handle.net/123456789/8314-
dc.description10p:, ill.en_US
dc.description.abstractHepatitis B Virus (HBV) infection is an important public health problem that requires high priority efforts towards prevention and control. Active immunization is the single most important and effective preventive measure against HBV infection. As a protective measure, Ghana introduced the mass immunization program against hepatitis B infection in children in 2002 in her Expanded Programme on Immunization (EPI). This study evaluated seroconversion (the point in time when the amount of antibody in the blood becomes detectable) and seroprotection (the point in time when the amount of antibody in the blood is enough to confer protection from the antigen that induced it production) status of children under this mass immunization program and measured their antibody levels five years after immunization.en_US
dc.language.isoenen_US
dc.publisherUniversity of Cape Coasten_US
dc.titleSeroconversion of Hepatitis B Vaccine in Young Children in the Kassena Nankana District of Ghana: A Cross-Sectional Studyen_US
dc.typeArticleen_US
Appears in Collections:School of Allied Health Sciences

Files in This Item:
File Description SizeFormat 
HBVVACCINE.pdfArticle821.85 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.